Where does CB Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CB Therapeutics, Inc. ranks #24,071 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CB Therapeutics, Inc. hold?

CB Therapeutics, Inc. holds 11 US utility patents granted between 2017 and 2024, spanning 11 technology areas.

What is CB Therapeutics, Inc.'s Innovation Score?

CB Therapeutics, Inc. has an Innovation Score of 31.8 out of 100 (39th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is CB Therapeutics, Inc.'s patent grant rate increasing or decreasing?

CB Therapeutics, Inc.'s recent grant velocity is +75% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for CB Therapeutics, Inc.'s patents?

CB Therapeutics, Inc.'s patents average 15.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CB Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CB Therapeutics, Inc.

Q: What technology areas does CB Therapeutics, Inc. focus on?

CB Therapeutics, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 7 patents, ranking #1,382 of 4,144 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

USPTO PatentsView assignee record - 11 granted patents across 11 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, CB ranks #24,071 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 11 technology areas.

#24,071
of 49,997 US assignees by volume: 39th percentile
by Innovation Score (31.8/100): 15.9
avg claims per patent: +75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24071 · US Corporation #24,071 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,071/49,997
PHOTO-FINISH Cardioflow
CPC-FOCUS C12N · 11 areas
INNOV-THIN 31.8/100
CLAIMS-RICH 15.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +75% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cardioflow Technologies, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How CB’s 31.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (27%) Velocity 1.9 pts (6%) Breadth 11.7 pts (37%) Claim depth 9.5 pts (30%)

Qualcomm Incorporated · highest

85
CB Therapeutics · this assignee

32
3D Lighting… · lowest

7

What this shows CB's Innovation Score is 31.8/100 (39th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for CB?

Each dot is one of CB’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). CB’s own 15.9 claims/patent is ABOVE the 13.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

CB vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where CB's grants concentrate

CB Therapeutics, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 63.6% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2020. By volume, CB sits between Cardioflow Technologies, LLC and Centre Technique DES Industries Mecaniques.

CB's three-year grant acceleration

CB Therapeutics, Inc. shows 2 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cardioflow

11
Cardiologs SAS

11
Carimali S P A

11
Carponovum AB

11
Cejn AB

11
Celonova Bioscien…

11
Cemex Research Gr…

11
Centre Technique…

11
CB Therapeutics ◀

11

What this shows CB holds 11 patents at rank #24,053, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CB

By rank, the assignees closest to #24,053 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in CB's primary technology class.

CB's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 39th percentile higher than 39% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

CB Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	18.2%
2019	2	18.2%
2020	1	9.1%
2021	4	36.4%
2022	1	9.1%
2024	1	9.1%

Which technologies does CB Therapeutics, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 6

C07K - Peptides 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

C12Y - Enzymes 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 2

C07D - Heterocyclic Compounds 2

G06F - Electric Digital Data Processing 1

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CB Therapeutics, Inc.'s patent record in context - here's where to go next.

CB Therapeutics, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 63.6% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #24,071 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CB Therapeutics, Inc. against Cardioflow Technologies, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.